Japan
-
Olympus to launch CADDIE PLUS AI Colonoscopy Solution in Europe in November 2026
CADDIE PLUS builds on the existing CADDIE system by adding real time polyp size classification and withdrawal time monitoring to help endoscopists assess lesions and monitor procedural quality.
-
Asahi Kasei unifies global pharma business to target US$1.9B in revenue by 2030
It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.
-
OMRON marks 40 years of Ohasama Study advancing home blood pressure monitoring
Researchers from Tohoku University launched the study in 1986 under Professor Yutaka Imai in response to the high burden of hypertension and stroke in Ohasama, Iwate Prefecture.
-
GSK gains first global approval for Bepirovirsen as Japan clears new hepatitis B functional cure
The antisense oligonucleotide (ASO) medicine, which GSK will market in Japan as Hibsago, is approved for adults with hepatitis B who meet specified viral markers.
-
Olympus launches ENDOEYE FLEX 3D videoscope for advanced endoscopic surgery
The new videoscope combines 4K, 3D and infrared (IR) imaging in a single device, allowing surgeons to switch between observation modes without changing scopes.
-
Olympus to distribute Endocision’s Celsio Cryocatheter globally for bronchoscopy procedures
The device uses controlled freezing to adhere to and remove targeted tissue or foreign material, enabling clinicians to perform both diagnostic and therapeutic interventions through a bronchoscope.
-
Eisai licenses preclinical oncology programmes to CORE Biomedicine
Under the agreement, CORE Biomedicine will evaluate and develop the licensed programmes with the aim of creating targeted treatments for a wider range of cancer patients.
-
Tanabe Pharma sells manufacturing unit and 17 off-patent drugs to Towa Pharmaceutical
The transaction, announced on July 3, includes Tanabe Pharma Factory’s production facilities in Onoda and Yoshitomi.
-
Asahi Kasei installs novel FO-MD system at Peptistar to speed up API manufacturing
The move marks an important step toward evaluating the technology for Good Manufacturing Practice (GMP)-compliant manufacturing while improving the efficiency of producing next-generation medicines.
-
Asahi Kasei Life Science licenses the Noguchi Institute ADC platform to advance precision biologic therapies
The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.